BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26516161)

  • 1. Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma.
    Ilmer M; Garnier A; Vykoukal J; Alt E; von Schweinitz D; Kappler R; Berger M
    Mol Cancer Ther; 2015 Dec; 14(12):2712-21. PubMed ID: 26516161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
    Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
    Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Babao Dan is a robust anti-tumor agent via inhibiting wnt/β-catenin activation and cancer cell stemness.
    Xie X; Chen J; Wo D; Ma E; Ning Y; Peng J; Zhu W; Ren DN
    J Ethnopharmacol; 2021 Nov; 280():114449. PubMed ID: 34332067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
    Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
    J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt/β-catenin signaling as a useful therapeutic target in hepatoblastoma.
    Sha YL; Liu S; Yan WW; Dong B
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31511432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Innovations for Targeting Hepatoblastoma.
    Garnier A; Ilmer M; Kappler R; Berger M
    Anticancer Res; 2016 Nov; 36(11):5577-5592. PubMed ID: 27793881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of Cancer Stemness by Novel Diterpenoid Ovatodiolide Inhibits Hepatic Cancer Stem Cell-Like Traits by Repressing Wnt/[Formula: see text]-Catenin Signaling.
    Liu M; Bamodu OA; Kuo KT; Lee WH; Lin YK; Wu ATH; M H; Tzeng YM; Yeh CT; Tsai JT
    Am J Chin Med; 2018; 46(4):891-910. PubMed ID: 29792038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFβ signaling.
    Matsumoto S; Yamamichi T; Shinzawa K; Kasahara Y; Nojima S; Kodama T; Obika S; Takehara T; Morii E; Okuyama H; Kikuchi A
    Nat Commun; 2019 Aug; 10(1):3882. PubMed ID: 31462641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
    Muñoz M; Berger M; Rosso M; Gonzalez-Ortega A; Carranza A; Coveñas R
    Int J Oncol; 2014 Jan; 44(1):137-46. PubMed ID: 24190675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
    Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
    Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
    Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
    Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
    Ellerkamp V; Lieber J; Nagel C; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Pediatr Surg Int; 2013 Feb; 29(2):141-9. PubMed ID: 23266718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
    Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
    Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
    Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
    Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1.
    Canal F; Anthony E; Lescure A; Del Nery E; Camonis J; Perez F; Ragazzon B; Perret C
    BMC Cancer; 2015 Dec; 15():1020. PubMed ID: 26715116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-
    Ghahremanloo A; Javid H; Afshari AR; Hashemy SI
    Biomed Res Int; 2021; 2021():1383878. PubMed ID: 34395609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quercetin inhibited the proliferation and invasion of hepatoblastoma cells through facilitating SIRT6-medicated FZD4 silence.
    Liu T; Li Z; Tian F
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S96-S107. PubMed ID: 34219513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.
    Zhang W; Meyfeldt J; Wang H; Kulkarni S; Lu J; Mandel JA; Marburger B; Liu Y; Gorka JE; Ranganathan S; Prochownik EV
    J Biol Chem; 2019 Nov; 294(46):17524-17542. PubMed ID: 31597698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KDM1A drives hepatoblastoma progression by activating the Wnt/β-catenin pathway through inhibition of DKK3 transcription.
    Ji C; Chen L; Yuan M; Xie W; Sheng X; Yin Q
    Tissue Cell; 2023 Apr; 81():101989. PubMed ID: 36642006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.